Synthorx Inc. (THOR) – Press Releases
-
Sanofi : Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion
-
Synthorx to Present at Upcoming Investor Conferences
-
Synthorx to Present at Upcoming Investor Conferences
-
Synthorx Reports Third Quarter Financial Results
-
Synthorx Reports Third Quarter Financial Results
-
Synthorx to Present THOR-809 Data at the American College of Rheumatology (ACR) Annual Meeting
-
Synthorx to Present THOR-809 Data at the American College of Rheumatology (ACR) Annual Meeting
-
Synthorx to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
-
Synthorx to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
-
Synthorx to Present at the European Society for Medical Oncology (ESMO) 2019 Congress
-
Synthorx to Present at the European Society for Medical Oncology (ESMO) 2019 Congress
-
Synthorx to Present at the 2019 World Congress of Inflammation
-
Synthorx to Present at the 2019 World Congress of Inflammation
-
Synthorx to Present at H.C. Wainwright 21st Annual Global Investment Conference
-
Synthorx to Present at H.C. Wainwright 21st Annual Global Investment Conference
-
Synthorx Reports Second Quarter Financial Results
-
Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707
-
Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707
-
Synthorx to Present at Jefferies 2019 Healthcare Conference
-
Synthorx to Present at Jefferies 2019 Healthcare Conference
-
Synthorx to Present at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Synthorx to Present at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Synthorx Reports First Quarter Financial Results
-
Synthorx Reports First Quarter Financial Results
-
Synthorx to Present at H.C. Wainwright Global Life Sciences Conference in London
-
Synthorx to Present at H.C. Wainwright Global Life Sciences Conference in London
-
Synthorx to Present at the American Association of Cancer Research (AACR) Annual Meeting 2019
-
Synthorx to Present at the American Association of Cancer Research (AACR) Annual Meeting 2019
-
Synthorx Reports Fourth Quarter and Full Year 2018 Financial Results
-
Synthorx Reports Fourth Quarter and Full Year 2018 Financial Results
-
Synthorx to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy
-
Synthorx to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy
-
Synthorx to Present at the 8th Annual SVB Leerink Global Healthcare Conference
-
Synthorx to Present at the 8th Annual SVB Leerink Global Healthcare Conference
-
Synthorx Appoints Andrew Powell, J.D., to its Board of Directors
-
Synthorx Appoints Andrew Powell, J.D., to its Board of Directors
-
Synthorx Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Synthorx Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Synthorx Announces Pricing of Initial Public Offering
-
Synthorx Announces Pricing of Initial Public Offering
-
Intersect ENT Appoints David Lehman General Counsel
-
Thoratec Shareholders Approve St. Jude Medical's Acquisition Of Thoratec
-
Thoratec Highlights Clinical Events From The European Association For Cardio-Thoracic Surgery Conference
-
Verisk Analytics Set to Join the S&P 500; Joy Global to Join S&P MidCap 400
-
HeartMate 3™ CE Mark Trial Meets Primary Endpoint
-
Thoratec Issues Voluntary Device Correction
-
Thoratec Announces Start Of Shield II™ U.S. Clinical Trial
-
Thoratec Announces End Of "Go Shop" Period
-
Thoratec® Reports Second Quarter 2015 Results
-
Lifshitz & Miller Law Firm Announces Investigation of Celladon Corporation, Edison International, Inc., Louisiana Bancorp, Inc., Navient Corp., On Deck Capital, Inc., Thoratec, and Vivint Solar
Back to THOR Stock Lookup
